Tue, Sep 23, 2014, 8:35 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Ironwood Pharmaceuticals, Inc. Message Board

galaberge 106 posts  |  Last Activity: Sep 22, 2014 7:38 PM Member since: Mar 5, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • The Abstract presented by the Dr. Voskhul on Friday 12th 2014

    If you are interested in what Dr. Voskhul has presented on Friday 12th 2014 here is the address :(Beware this a website not Secure so remove manually the S)

    Here is :"professionalabstractsDOTcom/msboston2014/planner/indexDOTphp?go=abstract&action=abstract_show&absno=1273&MSBOSTON2014=4d1asi8qa2ctssfv359h9uhfsvokkdv5"

    She had only 12 minutes to do her presentation hence some parts are verbal only....

    I think she was not supposed to present this abstract while writing her paper for a specialised medicine journal.

    Long and strong SYN

    Sentiment: Strong Buy

  • The only TINY criticism came from Mr. Bruce Bebo, The Multiple Sclerosis Society's associate vice president of discovery research who said: "Neurodegeneration is an aspect of MS not addressed by current therapies. Judgment needs to be reserved UNTIL WE SEE THE PAPER PUBLISHED IN A JOURNAL. But I think this is VERY ENCOURAGING."----Period!

    I encourage you to read the answer of Dr. Voskuhl when presenting the latest data at the American Academy of Neurology's recent convention, and saying she will soon submit it for review and publication in a journal. (It may be "The Lancet" in UK or "The New England Journal of Medicine" in USA. She has said that in last June 2014!!!

    Go and google the following: “Female hormone estriol showing promise as MS therapy"- to be sure of the wording.

    So Dr. Voskuhl is now preparing the publication of a paper in a prestigious journal and it may take several months. After the publication NOTHING can go wrong. The FDA approval will follow.

    Long and strong SYN

    Sentiment: Strong Buy

  • Go to the page where Dr. Voskhul is speaking in "common" words. Just go to "articlesDOTphillyDOTcom/2014-06-05/news/50333093_1_estriol-rhonda-voskuhl-ms-therapy"

    This article is so well presented that it should be the PR !

    After read caefully the article published in the "Laboratory Investigation' ( I mentionned this in a previous post ) :"natureDOTcom/labinvest/journal/v92/n8/full/labinvest201276aDOThtml" for further information and clarification of the different terms//words used to understand TRIMESTA is a real success.

    Don't forget to remove the DOT and replace them with real dots !

    We are in the pole position and so Long and Strong SYN.

    Sentiment: Strong Buy

  • galaberge galaberge Sep 13, 2014 11:29 AM Flag

    My answers have been deleted 2 times by Yahoo !!!!!!!!

    Sentiment: Strong Buy

  • His new companies have avoided venture capital.

    So SYN meets his requirements.

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Sep 13, 2014 8:47 AM Flag

    ......that....sorry for the typo error.

    Sentiment: Strong Buy

  • Just read part of my DD........

    "Mr. Riley has more than 23 years of experience in the biotechnology and pharmaceutical industries during which he negotiated numerous worldwide strategic corporate alliances, established joint ventures, and assisted in obtaining venture financings to support product development. Currently, Mr. Riley is Managing Director of Black Crow Ventures, a life science-focused consulting firm with a commercial and transactional focus. He sits on the advisory boards of an Australia-based venture fund (Queensland Biocapital Fund) and Ruga Corporation, a Stanford University spin-out drug discovery company focused on endoplasmic reticulum stress targets.

    Mr. Riley has held senior corporate and commercial development positions with biotech companies Amphora Discovery, Ontogen Corporation, and AvMax. In these positions, he was responsible for raising equity and negotiating alliances including in-licensing, out-licensing, distribution agreements, technology acquisitions and research agreements with large pharmaceutical companies and government agencies. Mr. Riley's pharmaceutical experience includes commercial management and mergers and acquisition roles for PFIZER and SmithKline Beecham. Additionally, Mr. Riley served as CFO and VP Corporate Development for Nichols Institute Diagnostics, a CLIA-certified molecular diagnostics and reference lab, later acquired by Quest Diagnostics. Prior to attending university, Mr. Riley served in the U.S. Army."

    He can help to find a partner for SYN very easily with Randal J. Kirk-the $3 BILLION-man who owns virtually SYN.

    Long and strong SYN

    Sentiment: Strong Buy

  • .........them from damage. None of the other drugs do that.

    I quote the "Laboratory Investigation" :

    "Peripheral and Central Nervous System

    Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease ! Estriol treatment prevented decreases in excitatory synaptic transmission and lessened the effect of MS (in animals) on PPF (paired-pulse facilitation). In addition, Estriol treatment prevented several neuropathological alterations that occurred in the hippocampus during MS. Cross-modality correlations revealed that deficits in excitatory synaptic transmission were significantly correlated with reductions in trans-synaptic protein binding partners known to modulate excitatory synaptic transmission. To our knowledge, this is the first report describing a functional correlate to hippocampal neuropathology in any MS model. Furthermore, a treatment was identified that prevented both deficits in synaptic function and hippocampal neuropathology...and it's Estriol"

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    REPAIR -- neuroprotective benefits!

    by don_quixote123456 Sep 12, 2014 9:29 AM
    galaberge galaberge Sep 12, 2014 11:40 AM Flag

    By far the best strategy in terms of negotiation and the overall Synthetic business. Results of this morning are more precise than in April and prove SYN was right. Patience. Just watch the coming weeks for other news.

    Long and strong SYN

    Sentiment: Strong Buy

  • Do you think you are brilliant with such way of doing business? You have been ousted and it was a great decision from the new owner.

    Long and strong SYN

    Sentiment: Strong Buy

  • Reply to

    Trimesta Deal

    by mdr0418 Sep 11, 2014 12:09 PM
    galaberge galaberge Sep 11, 2014 1:21 PM Flag

    MDR0418- As always you are right on with your assumptions. I like to read all your posts well written and supported with facts.

    Long and strong SYN

    Sentiment: Strong Buy

  • With his right arm Jeff. Riley running Synthetic we are going to where the others don't want to go.

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Sep 11, 2014 7:29 AM Flag

    I was expecting the CEO would do that. It's a very important event Friday and all the shareholders wants to hear directly from the CEO what are the results. Good initiative from Mr. Riley to continue to be in close contact with the shareholders.

    UGT- For your information and for others I am a man and not a woman. I am Chemical engineer basically, I hold a Ms in Biology and have worked over 20 years in researches for an important company. I am also a French so it explains my written so-so English : I work to improve it.

    Have a good day.

    Congrats to SYN management for their initiative to host a CC tomorrow before the opening of the markets. It's well appreciated. We all hope GOOD NEWS.

    Long and srong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Sep 10, 2014 6:54 PM Flag

    The data will be presented at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) in Boston.

    The abstract titled, "A Combination Trial of Estriol Plus Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis: Effects on Disabilities", will be featured in an oral presentation on Friday, September 12, 2014, at 8:39am (ET).

    Sentiment: Strong Buy

  • She has all the datas on hand. She has studied MS for years. She has made numerous clinical trials. Let's go for her best achievement in front of this special audience of neurologists when she will deliver all her Trimesta findings.

    The patients, the shareholders and the Big Boys of SYN are waiting.

    It's not the time to fail. It's time for success.

    Long and strong SYN.

    Sentiment: Strong Buy

  • galaberge galaberge Sep 9, 2014 3:42 PM Flag

    I don't know what are the other conditions. The only thing important before the conference of Dr. Voskhul is the following ".....Trends for improvement in the Expanded Disability Status Scale (EDSS) were seen at 24 months in the estriol plus glatiramer acetate group, but NOT IN THE PLACEBO plus glatiramer acetate (COPAXONE) group..."

    So we have the proof that ESTRIOL after 2 years works perfectly while COPAXONE DON'T WORK AT ALL.....!!

    We will have more details Friday the 12th.

    Long and strong SYN

    Sentiment: Strong Buy

  • galaberge galaberge Sep 9, 2014 11:43 AM Flag

    .......................continuation

    Methods: Analyses of secondary endpoints were done on data from a randomized, double-blind, multicenter, placebo-controlled (1:1) trial of oral estriol 8 mg per day in RRMS women, age 18-50 years. Estriol was an add-on therapy. Thus, all subjects began glatiramer acetate injections within 2 months or less of randomization and received either estriol versus placebo pills to take in combination. Treatment duration was 2 years. The primary endpoint was annualized relapse rate.
    Results: The estriol plus glatiramer acetate group as compared to the placebo plus glatiramer acetate group had improved cognitive testing scores after 12 months of treatment as demonstrated by the Paced Auditory Serial Addition Test (PASAT). After 24 months of treatment, test scores remained high in the estriol plus glatiramer acetate group, while scores in the placebo plus glatiramer acetate group also improved. Effects on the Selective Reminding Test and the Spatial Recall Test were examined in the context of effects on the PASAT. Trends for improvement in the Expanded Disability Status Scale (EDSS) were seen at 24 months in the estriol plus glatiramer acetate group, but not in the placebo plus glatiramer acetate group. Effects on the 25 foot walk test were examined in the context of effects on the EDSS. Correlations between serum estriol levels and effects on MS disabilities were also investigated.
    Conclusions: Effects of treatment of RRMS women with a dose of estriol physiologic with pregnancy will be discussed with respect to known neuroprotective effects of estrogens in other conditions.

    Assigned speakers:
    M.D. Rhonda Voskuhl , UCLA , Los Angeles , US


    Assigned in sessions:
    12.09.2014, 08:15-09:15, Free communications, FC3, Free Communication 3 (FC3.1-FC3.5), Grand Ballroom

    Long and Strong SYN

    Sentiment: Strong Buy

  • A combination trial of estriol plus glatiramer acetate in relapsing-remitting multiple sclerosis: effect on disabilities

    R Voskuhl1, H Wang1, G Lee1, B Giesser1, CH Tse1, R Elashoff1, Estriol Relapse Trial Study Group
    1University of California, Los Angeles, CA, United States

    Background: Pregnancy is known to be a period of relative protection from MS relapses. Estriol is an estrogen which gradually increases during pregnancy, reaching high levels in the last trimester. Beneficial effects of estrogen treatment, including estriol, have included both anti-inflammatory and neuroprotective mechanisms in MS models. In a recently completed Phase II trial in women with relapsing remitting MS (RRMS), relapse rates were decreased in subjects treated with the combination of estriol plus glatiramer acetate as compared to placebo plus glatiramer acetate. Treatment was safe and well tolerated.
    Objectives: Given the known neuroprotective effects of estrogens in nonMS conditions, particularly as related to cognition, secondary outcomes in the completed trial were investigated for effects of treatment on cognitive and other MS disabilities.

    Continued..............1/2

    Sentiment: Strong Buy

  • Jeffrey Riley, CEO, is scheduled to present at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. Mr. Riley is scheduled to present at 10:25 a.m. (Eastern Time) on Tuesday, September 9, 2014 at the New York Palace Hotel in New York City.

    A live webcast of Synthetic Biologics’ presentation may be accessed by logging onto the internet at the company's website.

    After the presentation, a replay will be archived and accessible for 30 days at the same website.

    It should be very interesting the Q/A....

    Long and strong SYN

    Sentiment: Strong Buy

IRWD
12.19-0.08(-0.65%)Sep 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Allergan Inc.
NYSETue, Sep 23, 2014 4:01 PM EDT